FI20055417A0 - Syöpäpesifiset glykaanit ja niiden käyttö - Google Patents

Syöpäpesifiset glykaanit ja niiden käyttö

Info

Publication number
FI20055417A0
FI20055417A0 FI20055417A FI20055417A FI20055417A0 FI 20055417 A0 FI20055417 A0 FI 20055417A0 FI 20055417 A FI20055417 A FI 20055417A FI 20055417 A FI20055417 A FI 20055417A FI 20055417 A0 FI20055417 A0 FI 20055417A0
Authority
FI
Finland
Prior art keywords
glycans
cancer
present
methods
malignancies
Prior art date
Application number
FI20055417A
Other languages
English (en)
Swedish (sv)
Inventor
Tero Satomaa
Jari Natunen
Annamari Heiskanen
Anne Olonen
Noora Salovuori
Juhani Saarinen
Original Assignee
Glykos Finland Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glykos Finland Oy filed Critical Glykos Finland Oy
Priority to FI20055417A priority Critical patent/FI20055417A0/fi
Publication of FI20055417A0 publication Critical patent/FI20055417A0/fi
Priority to FI20060453A priority patent/FI20060453A0/fi
Priority to AT06764481T priority patent/ATE553382T1/de
Priority to EP11189389.7A priority patent/EP2431743B1/en
Priority to EP06764481A priority patent/EP1910838B1/en
Priority to CA002658311A priority patent/CA2658311A1/en
Priority to US11/989,031 priority patent/US20090117106A1/en
Priority to DK06764481.5T priority patent/DK1910838T3/da
Priority to PCT/FI2006/000263 priority patent/WO2007010089A2/en
Priority to US14/523,154 priority patent/US20150140576A1/en
Priority to US15/264,650 priority patent/US20170002095A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
FI20055417A 2005-07-20 2005-07-20 Syöpäpesifiset glykaanit ja niiden käyttö FI20055417A0 (fi)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FI20055417A FI20055417A0 (fi) 2005-07-20 2005-07-20 Syöpäpesifiset glykaanit ja niiden käyttö
FI20060453A FI20060453A0 (fi) 2005-07-20 2006-05-09 Syöpäspesifiset glykaanit ja niiden käyttö
PCT/FI2006/000263 WO2007010089A2 (en) 2005-07-20 2006-07-20 Cancer specific glycans and use thereof
EP06764481A EP1910838B1 (en) 2005-07-20 2006-07-20 Uses of cancer specific glycans
EP11189389.7A EP2431743B1 (en) 2005-07-20 2006-07-20 Cancer specific glycans and use thereof
AT06764481T ATE553382T1 (de) 2005-07-20 2006-07-20 Verwendungen von krebsspezifischen glykanen
CA002658311A CA2658311A1 (en) 2005-07-20 2006-07-20 Cancer specific glycans and use thereof
US11/989,031 US20090117106A1 (en) 2005-07-20 2006-07-20 Cancer Specific Glycans and Use Thereof
DK06764481.5T DK1910838T3 (da) 2005-07-20 2006-07-20 Anvendelser af cancerspecifikke glycaner
US14/523,154 US20150140576A1 (en) 2005-07-20 2014-10-24 Cancer specific glycans and use thereof
US15/264,650 US20170002095A1 (en) 2005-07-20 2016-09-14 Cancer specific glycans and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20055417A FI20055417A0 (fi) 2005-07-20 2005-07-20 Syöpäpesifiset glykaanit ja niiden käyttö

Publications (1)

Publication Number Publication Date
FI20055417A0 true FI20055417A0 (fi) 2005-07-20

Family

ID=34803283

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20055417A FI20055417A0 (fi) 2005-07-20 2005-07-20 Syöpäpesifiset glykaanit ja niiden käyttö

Country Status (7)

Country Link
US (3) US20090117106A1 (fi)
EP (2) EP2431743B1 (fi)
AT (1) ATE553382T1 (fi)
CA (1) CA2658311A1 (fi)
DK (1) DK1910838T3 (fi)
FI (1) FI20055417A0 (fi)
WO (1) WO2007010089A2 (fi)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1904532A4 (en) * 2005-07-11 2011-11-16 Suomen Punainen Risti Veripalvelu NEW CARBOHYDRATE PROFILE COMPOSITIONS FROM HUMAN CELLS AND METHOD FOR THEIR ANALYSIS AND MODIFICATION
JP5704917B2 (ja) * 2007-06-02 2015-04-22 セルノ・バイオサイエンス・エルエルシー 質量分析のための自己較正アプローチ
WO2009069776A1 (ja) * 2007-11-30 2009-06-04 National University Corporation Hokkaido University 糖鎖分析による肝疾患の診断方法
EP2354790B1 (en) * 2008-12-03 2013-07-17 The Noguchi Institute Method for determining prostate cancer
US9029530B2 (en) 2009-01-02 2015-05-12 Biomarin Pharmaceutical Inc. Detection of oligosaccharides
US8809009B2 (en) 2009-01-02 2014-08-19 Biomarin Pharmaceutical Inc. Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker
US8183003B2 (en) 2009-01-02 2012-05-22 Zacharon Pharmaceuticals, Inc. Polymer end group detection
US8232073B2 (en) * 2009-01-02 2012-07-31 Zacharon Pharmaceuticals, Inc. Quantification of non-reducing end glycan residual compounds
KR101456096B1 (ko) * 2013-04-04 2014-11-03 충남대학교산학협력단 인간 혈청 당쇄 지도 및 이를 이용하여 혈청 시료를 검증하는 방법
KR20230048153A (ko) 2014-01-27 2023-04-10 몰레큘러 템플레이츠, 인코퍼레이션. 폴리펩티드를 전달하는 mhc 클래스 i 항원결정기
CA2937524A1 (en) 2014-02-05 2015-08-13 Molecular Templates, Inc. Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
ES2864124T3 (es) 2014-03-11 2021-10-13 Molecular Templates Inc Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
CA2940218A1 (en) 2014-03-11 2015-09-17 Molecular Templates, Inc. Proteins comprising amino-terminal proximal shiga toxin a subunit effector regions and cell-targeting immunoglobulin-type binding regions
EP3514168B1 (en) 2014-06-11 2021-09-01 Molecular Templates, Inc. Protease-cleavage resistant cytotoxic cell-targeting molecules
IL292708B1 (en) 2015-05-30 2024-04-01 Molecular Templates Inc Vaccine-free Shiga toxin A subunit scaffolds and cell-targeting molecules containing them
MX2018001208A (es) 2015-07-26 2018-03-26 Molecular Templates Inc Moleculas con direccion a las celulas que comprenden efectores de la subunidad a de la toxina shiga y epitopos de celulas-t cd8+.
JP6834747B2 (ja) * 2016-05-18 2021-02-24 東ソー株式会社 肺癌を検出する方法及び検出用キット
CA3049456A1 (en) 2017-01-25 2018-08-02 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
CN109142506B (zh) * 2017-06-18 2022-03-18 复旦大学 一种基于质谱的n-糖链相对定量的方法
US10837970B2 (en) 2017-09-01 2020-11-17 Venn Biosciences Corporation Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring
IL268443B1 (en) 2018-04-17 2024-03-01 Molecular Templates Inc HER2-targeted molecules containing Shiga toxin subunit A scaffolds, without vaccination
WO2022087331A1 (en) * 2020-10-22 2022-04-28 Basf Se A method for measuring concentration of human milk oligosaccharides (hmo) molecules using glocometer
IL301880A (en) * 2020-11-30 2023-06-01 Janssen Pharmaceuticals Inc Analytical method for glycoconjugation using a capillary-based immunoassay system
CA3232387A1 (en) 2021-09-13 2023-03-16 Ganna Bio, Inc. Glycan conjugate compositions and methods
CN113960232B (zh) * 2021-10-28 2024-02-20 苏州大学 一种基于唾液特异性岩藻糖基化结构糖谱及其检测方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983004311A1 (en) 1982-06-03 1983-12-08 Otsuka Pharmaceutical Co., Ltd. Process for preparing fucose antigen and antibody for distinguishing it, measurement of tumor-associated sugar chain utilizing the same, and kit for the measurement
US5171667A (en) 1985-04-04 1992-12-15 Fred Hutchinson Cancer Research Center Hybridomas producing monoclonal antibodies to mono-, di- and trifucosylated type 2 chain
US4904596A (en) 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
US4851511A (en) 1986-01-30 1989-07-25 Fred Hutchinson Cancer Research Center Monoclonal antibody that specifically binds to disialosyl Lea
US5059520A (en) 1986-08-27 1991-10-22 Sloan-Kettering Institute For Cancer Research Monoclonal antibody panel for blood group a antigen
US5660834A (en) 1988-03-11 1997-08-26 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with carbohydrate-carrier conjugates
US5229289A (en) 1988-03-11 1993-07-20 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates
US5173292A (en) 1988-06-14 1992-12-22 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies which specifically recognize galactosyl-globoside, compositions containing same and methods of using same
US5102663A (en) 1988-10-18 1992-04-07 Sloan-Kettering Instutute For Cancer Research Vaccine for stimulating or enhancing production of antibodies against 9-O-acetyl GD3
US6083929A (en) 1991-05-06 2000-07-04 The Biomembrane Institute Extended type 1 chain glycosphingolipids as tumor-associated antigens
JPH0646880A (ja) 1992-07-28 1994-02-22 Tosoh Corp モノクロ−ナル抗体およびその製造方法
JPH06172219A (ja) 1992-12-09 1994-06-21 Tosoh Corp 癌関連医薬品組成物
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5708163A (en) 1994-03-15 1998-01-13 Sloan-Kettering Institute Of Cancer Research Synthesis of the breast tumor-associated antigen defined by monoclonalantibody MBRL and uses thereof
US5795961A (en) 1995-02-14 1998-08-18 Ludwig Institute For Cancer Research Recombinant human anti-Lewis b antibodies
AU720802B2 (en) 1996-07-03 2000-06-15 Millenium Pharmaceuticals, Inc. Detection of cancer by assaying for cancer-specific antigens having linked oligosaccharides which are at least triantennary
JPH1084963A (ja) 1996-09-12 1998-04-07 Tosoh Corp 分岐ムチン型合成糖脂質を認識する抗体の遺伝子断片等
WO2000061636A2 (en) * 1999-04-14 2000-10-19 Research Corporation Technologies, Inc. Aberrantly glycosylated antibodies as marker for cancer
FI20011664A (fi) * 2001-08-17 2003-02-18 Carbion Oy Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
FI20011671A (fi) * 2001-08-20 2003-02-21 Carbion Oy Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
WO2003059924A1 (en) * 2002-01-18 2003-07-24 Biotie Therapies Corporation Novel binding epitopes for helicobacter pylori and use thereof
AU2002950878A0 (en) * 2002-08-20 2002-09-12 Proteome Systems Intellectual Property Pty Ltd Method for diagnosing disorders
US20040147033A1 (en) * 2002-12-20 2004-07-29 Zachary Shriver Glycan markers for diagnosing and monitoring disease
JP2008539412A (ja) * 2005-04-26 2008-11-13 レイモンド， エー． ドウェック， 癌の診断及びモニタリングのためのグリコシル化マーカー

Also Published As

Publication number Publication date
EP1910838B1 (en) 2012-04-11
EP1910838A4 (en) 2009-03-18
EP2431743B1 (en) 2018-05-30
CA2658311A1 (en) 2007-01-25
WO2007010089A2 (en) 2007-01-25
US20090117106A1 (en) 2009-05-07
DK1910838T3 (da) 2012-07-16
EP2431743A3 (en) 2012-07-18
EP1910838A2 (en) 2008-04-16
US20150140576A1 (en) 2015-05-21
WO2007010089A3 (en) 2007-05-31
US20170002095A1 (en) 2017-01-05
EP2431743A2 (en) 2012-03-21
ATE553382T1 (de) 2012-04-15

Similar Documents

Publication Publication Date Title
FI20055417A0 (fi) Syöpäpesifiset glykaanit ja niiden käyttö
EA200801037A1 (ru) Ингибиторы фосфатидилинозит-3-киназы и способы их применения
WO2005123993A3 (en) Phage microarray profiling of the humoral response to disease
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2009019368A3 (fr) Procede de dosage de la liver fatty acid-binding protein, de l'ace et du ca19-9 pour le diagnostic in vitro du cancer colorectal
WO2006119365A3 (en) Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
WO2006133923A3 (en) Diagnosis, prognosis and prediction of recurrence of breast cancer
WO2006012646A3 (en) Amacr cancer markers
WO2007056049A3 (en) Molecular profiling of cancer
WO2011057034A3 (en) Catenae: serosal cancer stem cells
NZ592432A (en) Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
WO2010093742A8 (en) Methods and compositions for identifying, classifying and monitoring subject having bcl-2 family inhibitor-resistant tumors and cancers
WO2006095086A3 (fr) Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence.
WO2009108917A3 (en) Markers for improved detection of breast cancer
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
WO2009020645A3 (en) Matriptase protein and uses thereof
WO2009019369A3 (fr) Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal
WO2012166700A3 (en) Molecular profiling of a lethal tumor microenvironment
WO2006052975A3 (en) Tumor association of mdl-1 and methods
WO2009154790A3 (en) Novel metastasis suppressor genes and uses thereof
WO2004101762A3 (en) Detection and treatment of cancers of the colon
WO2007068449A3 (de) Molekulare marker für eine tumordiagnose und -therapie
EA200802356A1 (ru) Способ выявления и диагностики злокачественного новообразования, включающий праймеры и зонды для специфичного выявления маркера mage-a3

Legal Events

Date Code Title Description
FD Application lapsed